Feature – Oncology Drug Treatment
Personalized medicine with tyrosine kinase inhibitors: the erlotinib case
Published in: Volume 7 / Year 2013 / Issue 2
Page: 32-33
Page: 32-33
Abstract:Large variability in the pharmacokinetics and pharmacodynamics of tyrosine kinase inhibitors warrants dose stratification rather than the use of fixed doses in all patients. Large population-based studies are required to… Read More »
